364 related articles for article (PubMed ID: 37726418)
1. Biomarkers for immunotherapy of hepatocellular carcinoma.
Greten TF; Villanueva A; Korangy F; Ruf B; Yarchoan M; Ma L; Ruppin E; Wang XW
Nat Rev Clin Oncol; 2023 Nov; 20(11):780-798. PubMed ID: 37726418
[TBL] [Abstract][Full Text] [Related]
2. Combination immunotherapy for hepatocellular carcinoma.
Rimassa L; Finn RS; Sangro B
J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
[TBL] [Abstract][Full Text] [Related]
3. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
4. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
5. The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.
Meyers BM; Knox JJ; Liu DM; McLeod D; Ramjeesingh R; Tam VC; Lim HJ
Cancer Treat Rev; 2023 Jul; 118():102584. PubMed ID: 37336142
[TBL] [Abstract][Full Text] [Related]
6. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
7. Sequencing Systemic Therapy in Hepatocellular Carcinoma.
Ponvilawan B; Roth MT
Curr Treat Options Oncol; 2023 Nov; 24(11):1580-1597. PubMed ID: 37843628
[TBL] [Abstract][Full Text] [Related]
8. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
[TBL] [Abstract][Full Text] [Related]
9. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
[TBL] [Abstract][Full Text] [Related]
10. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
[TBL] [Abstract][Full Text] [Related]
11. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
Feng MY; Chan LL; Chan SL
Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
[TBL] [Abstract][Full Text] [Related]
12. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
13. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
[TBL] [Abstract][Full Text] [Related]
14. Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis.
Rizzo A; Carloni R; Ricci AD; Cusmai A; Laforgia M; Calabrò C; Ungaro V; Oreste D; Sollitto M; Palmiotti G; Brandi G
Expert Opin Drug Saf; 2023 Apr; 22(4):323-329. PubMed ID: 36426773
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role?
Pinto E; Meneghel P; Farinati F; Russo FP; Pelizzaro F; Gambato M
Dig Liver Dis; 2024 Apr; 56(4):579-588. PubMed ID: 37758610
[TBL] [Abstract][Full Text] [Related]
16. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular Carcinoma Immunotherapy.
Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapies for hepatocellular carcinoma.
Llovet JM; Castet F; Heikenwalder M; Maini MK; Mazzaferro V; Pinato DJ; Pikarsky E; Zhu AX; Finn RS
Nat Rev Clin Oncol; 2022 Mar; 19(3):151-172. PubMed ID: 34764464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
